The two universities are located in the heart of a well-established eco-system of outstanding health service and medical research institute partners. Both universities sit comfortably in the world’s top 50 in medicine and pharmacology in the latest world rankings.
But when the research strengths of the two universities are combined in the therapeutic areas of immunology, oncology and infectious diseases, they would be placed among the top 10 institutions globally. And their respective strengths are highly compatible and complementary.
Together, they offer a strong pipeline of high quality drug candidates with the potential to make a significant impact medically and commercially.
The $A80 million collaboration initiative seeks to address the persistent market failures in Australia which sees too many important discoveries fail to progress out of the lab into new cures and therapies and those that do are too often taken offshore very early in their development so that much of their value is lost to Australia.
The new enterprise, a 'venture catalyst', will be jointly owned by the two Universities but will be operationally independent under a highly skilled board. It will bring the advanced commercialisation skills and access to funding needed to address successfully the early stage “valley of death”.
The new enterprise will seek to significantly increase the flow of high potential commercialisable opportunities from the researchers’ benches through to the stage of development at which existing investors and strategic corporations are willing and able to take over.
The demand for new drugs continues to grow, with the global pharma market estimated to increase by two thirds to $US1.5 trillion in the decade to 2020, and the pharma industry now increasingly seeking to source high-quality, de-risked new medicine candidates from external sources, who it then funds through to regulatory approval, manufacturing and marketing.
This collaboration makes compelling strategic sense but importantly it shows that governments, corporations and innovators/researchers need to show leadership and be willing to take imaginative and bold steps to create the environment where the great ideas can come to life and to market.
In this instance, two universities – fierce but respectful competitors – have found a way to unlock the potential for Melbourne to be a world class pharma hub and to do so building on existing facilities and infrastructure.
It’s just one example of how economic structures need to adapt to support the new economy. The crucial lesson for unlocking the potential of innovation - the philosopher’s stone - is enabling convergence through bringing people and resources together in support of attractive shared goals.
As well as being ANZ’s deputy chief financial officer and head of finance, Shane Buggle is a deputy chancellor of Monash University’s governing Council